Skip to main content

Dotarizine

Multi tool use
Multi tool use









Dotarizine


From Wikipedia, the free encyclopedia

Jump to navigation
Jump to search


























































Dotarizine
Dotarizine.png
Clinical data
Synonyms Dotarizine
ATC code
  • none
Identifiers
CAS Number

  • 84625-59-2 ☑Y

PubChem CID
  • 55285
ChemSpider

  • 49929 ☒N
UNII
  • IO7663S6D3
ChEBI
  • CHEBI:138033
ChEMBL

  • ChEMBL2106316 ☒N
Chemical and physical data
Formula
C29H34N2O2
Molar mass 442.592 g/mol
3D model (JSmol)
  • Interactive image

.mw-parser-output .nobold{font-weight:normal}
 ☒N☑Y (what is this?)
  (verify)

Dotarizine is a drug used in the treatment of migraine,[1] which acts as a calcium channel blocker,[2] and also as an antagonist at the 5HT2A receptor, and to a lesser extent at the 5HT1A and 5HT2C receptors.[3][4] The anti-migraine action is thought to be due to its action as a vasodilator,[5][6] but it also has some anxiolytic effects[7] and blocks amnesia produced by electroconvulsive shock in animals.[8]



References[edit]





  1. ^ Ruiz-Nuño, A; Villarroya, M; Cano-Abad, M; Rosado, A; Balfagón, G; López, MG; García, AG (2001). "Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility". European Journal of Pharmacology. 411 (3): 289–99. doi:10.1016/S0014-2999(00)00897-9. PMID 11164387..mw-parser-output cite.citation{font-style:inherit}.mw-parser-output q{quotes:"""""""'""'"}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}


  2. ^ Ruiz-Nuño, A; Mayorgas, I; Hernández-Guijo, JM; Olivares, R; García, AG; Gandía, L (2003). "Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells". European Journal of Pharmacology. 481 (1): 41–50. doi:10.1016/j.ejphar.2003.09.013. PMID 14637173.


  3. ^ Farré, M; Roset, PN; Llorente, M; Márquez, M; Albet, C; Pérez, JA; Herrero, E; Ortíz, JA (1997). "Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration". Methods and findings in experimental and clinical pharmacology. 19 (5): 343–50. PMID 9379783.


  4. ^ Montiel, C; Herrero, CJ; García-Palomero, E; Renart, J; García, AG; Lomax, RB (1997). "Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors". European Journal of Pharmacology. 332 (2): 183–93. doi:10.1016/S0014-2999(97)01073-X. PMID 9286620.


  5. ^ Kuridze, N; Gajkowska, B; Czernicki, Z; Jurkiewicz, J; Cervos-Navarro, J (1998). "The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia". Folia Neuropathologica. 36 (2): 101–8. PMID 9757621.


  6. ^ Kuridze, N; Czernicki, Z; Jarus-Dziedzic, K; Jurkiewicz, J; Cervos-Navarro, J (2000). "Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine". Journal of the Neurological Sciences. 175 (1): 13–6. doi:10.1016/S0022-510X(00)00275-6. PMID 10785251.


  7. ^ Petkov, VD; Belcheva, S; Konstantinova, E (1995). "Anxiolytic effects of dotarizine, a possible antimigraine drug". Methods and findings in experimental and clinical pharmacology. 17 (10): 659–68. PMID 9053586.


  8. ^ Lazarova, M; Petkova, B; Petkov, VD (1995). "Effect of dotarizine on electroconvulsive shock or pentylenetetrazol-induced amnesia and on seizure reactivity in rats". Methods and findings in experimental and clinical pharmacology. 17 (1): 53–8. PMID 7623521.





















Retrieved from "https://en.wikipedia.org/w/index.php?title=Dotarizine&oldid=859218095"





Navigation menu

























(window.RLQ=window.RLQ||).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"0.944","walltime":"1.133","ppvisitednodes":{"value":6272,"limit":1000000},"ppgeneratednodes":{"value":0,"limit":1500000},"postexpandincludesize":{"value":504900,"limit":2097152},"templateargumentsize":{"value":6460,"limit":2097152},"expansiondepth":{"value":16,"limit":40},"expensivefunctioncount":{"value":2,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":24774,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 725.447 1 -total"," 51.29% 372.079 1 Template:Drugbox"," 37.46% 271.716 39 Template:Navbox"," 35.13% 254.838 1 Template:Infobox"," 24.04% 174.387 1 Template:Reflist"," 20.36% 147.719 8 Template:Cite_journal"," 11.96% 86.745 16 Template:Unbulleted_list"," 10.40% 75.477 1 Template:Channelergics"," 6.76% 49.040 1 Template:Serotonergics"," 4.16% 30.203 1 Template:Infobox_drug/chemical_formula"]},"scribunto":{"limitreport-timeusage":{"value":"0.313","limit":"10.000"},"limitreport-memusage":{"value":5130386,"limit":52428800}},"cachereport":{"origin":"mw1320","timestamp":"20181215083926","ttl":1900800,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":113,"wgHostname":"mw1274"});});W1380StFjvk7o eQM,4 HTHH74k6GJ65X,Ap9fYdadlMdgkEh4wnGcvlNO,zW,PeYhEOeSF6J,vCXYPbvYY
-
jLLk2l,9Z6D,UIKDXgNa 9j6Ad

Popular posts from this blog

Full-time equivalent

Image
Full-time equivalent From Wikipedia, the free encyclopedia Jump to navigation Jump to search Full-time equivalent ( FTE ) or whole time equivalent ( WTE ) is a unit that indicates the workload of an employed person (or student) in a way that makes workloads or class loads comparable [1] across various contexts. FTE is often used to measure a worker's or student's involvement in a project, or to track cost reductions in an organization. An FTE of 1.0 is equivalent to a full-time worker or student, while an FTE of 0.5 signals half of a full work or school load. [2] Contents 1 U.S. Federal Government 2 In education 2.1 Example 3 Notes 4 References U.S. Federal Government [ edit ] In the U.S. Federal Government, FTE is defined by the Government Accountability Office (GAO) as the number of total hours worked divided by the maximum number of compensable hours in a full-time schedule as...
Read more

Haven (TV series)

Image
Haven (TV series) From Wikipedia, the free encyclopedia Jump to navigation Jump to search Haven Genre Supernatural drama Based on The Colorado Kid by Stephen King Developed by Sam Ernst Jim Dunn Starring Emily Rose Lucas Bryant Nicholas Campbell Eric Balfour Theme music composer Andre Fratto Leah Siegel Composer(s) Shawn Pierce Country of origin United States Canada Original language(s) English No. of seasons 5 No. of episodes 78 (list of episodes) Production Executive producer(s) Sam Ernst Jim Dunn David MacLeod John Morayniss Noreen Halpern Laszlo Barna Gabrielle Stanton Matt McGuiness Scott Shepherd Shawn Piller Lloyd Segan Production location(s) Nova Scotia, Canada Cinematography Eric Cayla Barry Donlevy Camera setup single Running time 41–43 minutes Production company(s) Big Motion Pictures Production...
Read more

さくらももこ

Image
さくら ももこ 本名 非公開 [1] 生誕 ( 1965-05-08 ) 1965年5月8日 日本・静岡県清水市 （現・静岡市清水区） 死没 ( 2018-08-15 ) 2018年8月15日（53歳没） 日本・東京都目黒区 国籍 日本 職業 漫画家 エッセイスト 作詞家 活動期間 1984年 - 2018年 ジャンル 少女漫画 青年漫画 児童漫画 代表作 『ちびまる子ちゃん』 『コジコジ』 受賞 1989年：第13回講談社漫画賞少女部門 （『ちびまる子ちゃん』） 1990年：第32回日本レコード大賞 （『おどるポンポコリン』作詞） 公式サイト さくらプロダクション テンプレートを表示 さくら ももこ （1965年5月8日 - 2018年8月15日 [2] ）は、日本の漫画家、エッセイスト、作詞家、脚本家。また、自身の少女時代をモデルとした代表作のコミック『ちびまる子ちゃん』の主人公の名前でもある。静岡県清水市（現・静岡市清水区）出身。血液型はA型。身長159cm。一男の母親。 代表作のコミック『ちびまる子ちゃん』の単行本の売上は累計3000万部を超える。また、エッセイストとしても独特の視点と語り口で人気が高く、初期エッセイ集三部作『もものかんづめ』『さるのこしかけ』『たいのおかしら』はいずれもミリオンセラーを記録。 目次 1 経歴 2 人物・交遊関係 3 主な作品 3.1 漫画 3.2 エッセイ 3.3 作詞 3.4 詩集 3.5 雑誌・ムック本 3.6 翻訳 3.7 絵本、ドラマ脚本他 3.8 ラジオ出演 3.9 その他 4 関係人物 4.1 アシスタント 4.2 さくらももこを演じた人物 5 脚注 5.1 注釈 5.2 出典 6 外部リンク 経歴 年譜形式の経歴は推奨されていません 。人物の伝記は流れのあるまとまった文章で記述し、年譜は補助的な使用にとどめてください。 （ 2018年8月 ） 清水市立（当時）入江小学校...
Read more